Table 3 revealed that serum levels of glucose, insulin, and HOMA-IR were dramatically increased (P < 0.05) in the MS group compared to the control, indicating decreased glucose tolerance and/or impaired insulin sensitivity. The gene discussed is INS; the disease is myeloid sarcoma.